David A. Kareken

David A. Kareken

Auto-generated profile, based on publicly available information

David A. Kareken

Indiana Alcohol Research Center, Indiana University School of Medicine, Indianapolis, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2003 in NeuroImage
Verified
Journal Article
Closed access
JRJean-P Royet
Jean-P Royet
JPJane Plailly
Jane Plailly
Chantal Delon-MartinChantal Delon-Martin
Chantal Delon-Martin
DKDavid A Kareken
David A Kareken
CSChristoph Segebarth
Christoph Segebarth

1 June 2005 in Archives of Clinical Neuropsychology
Verified
Journal Article
Open access
LBL Beglinger
L Beglinger
BGB Gaydos
B Gaydos
OTO Tangphaodaniels
O Tangphaodaniels
KDK Duff
K Duff
DKD Kareken
D Kareken
ESE Siemers
E Siemers
Accurate understanding of practice characteristics, performance stability, and error on neuropsychological tests is essential to both valid clinical assessment and maximization of signal detection for clinical trials of cognitive enhancing drugs. We examined practice effects in 28 healthy adults. As part of a larger study using donepezil and simulating a Phase I trial, participants were randomized into: placebo, no-treatment and donepezil. Donepezil results are presented elsewhere. Neuropsychological tests were administered in a fixed order for 6 weeks, with alternate forms available for most tests. Despite alternate forms, ANOVAs revealed significant improvements for the pooled control group (placebo and no-treatment) on all tests except Letter Number Sequencing and Trails B. Learning occurred principally in the first three to four sessions. PASAT and Stroop interference showed the greatest learning. Thus, serial assessment with alternate forms may attenuate retest effects on some tests, but continued learning occurs on novel tests or those in which an advantageous test-taking strategy can be identified. Alternate forms and baseline practice sessions may help control early, rapid improvements in clinical trials.

1 June 2002 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
BSBrian W. Sipe
Brian W. Sipe
DRDouglas K. Rex
Douglas K. Rex
DLDanielle Latinovich
Danielle Latinovich
COChris Overley
Chris Overley
KKKaren Kinser
Karen Kinser
DKDavid Kareken
David Kareken

1 March 2010 in Nursing Research
Verified
Journal Article
Closed access
SPSusan J. Pressler
Susan J. Pressler
USUsha Subramanian
Usha Subramanian
DKDavid Kareken
David Kareken
SPSusan M. Perkins
Susan M. Perkins
IGIrmina Gradus-Pizlo
Irmina Gradus-Pizlo
RSRose Mary Shaw
Rose Mary Shaw
Background: Patients with heart failure (HF) have been found to have cognitive deficits, but it remains unclear whether these deficits are associated with HF or with aging or comorbid conditions common in HF. Objectives: The purpose of this study was (a) to determine the types, the frequency, and the severity of cognitive deficits among patients with chronic HF compared with age- and education-matched healthy participants and participants with major medical conditions other than HF, and (b) to evaluate the relationships between HF severity, age, and comorbidities and cognitive deficits. Methods: A sample of 414 participants completed the study (249 HF patients, 63 healthy and 102 medical participants). The HF patients completed measures of HF severity, comorbidity (multiple comorbidity, depressive symptoms), and neuropsychological functioning. Blood pressure and oxygen saturation were assessed at interview; clinical variables were abstracted from records. Participants in the comparison groups completed the same measures as the HF patients except those specific to HF. Results: Compared with the healthy and medical participants, HF patients had poorer memory, psychomotor speed, and executive function. Significantly more HF patients (24%) had deficits in three or more domains. Higher (worse) HF severity was associated with more cognitive deficits; HF severity interacted with age to explain deficits in executive function. Surprisingly, men with HF had poorer memory, psychomotor speed, and visuospatial recall ability than women. Multiple comorbidity, hypertension, depressive symptoms, and medications were not associated with cognitive deficits in this sample. Discussion: HF results in losses in memory, psychomotor speed, and executive function in almost one fourth of patients. Patients with more severe HF are at risk for cognitive deficits. Older patients with more severe HF may have more problems in executive function, and men with HF may be at increased risk for cognitive deficits. Studies are urgently needed to identify the mechanisms for the cognitive deficits in HF and to test innovative interventions to prevent cognitive loss and decline.

8 April 2010 in American Journal of Critical Care
Verified
Journal Article
Closed access
PDF file
SPSusan J. Pressler
Susan J. Pressler
USUsha Subramanian
Usha Subramanian
SPSusan M. Perkins
Susan M. Perkins
IGIrmina Gradus-Pizlo
Irmina Gradus-Pizlo
DKDavid Kareken
David Kareken
RSRebecca Sloan
Rebecca Sloan
Background Depressive symptoms are common in patients with heart failure, but few investigators have reported the validity and reliability of measures of depressive symptoms among these patients. Objectives To evaluate the validity and reliability of a measure of depressive symptoms, the Patient Health Questionnaire–8 (PHQ-8), among 249 patients with chronic heart failure. Methods As part of a larger study, patients completed the PHQ-8 and the Living With Heart Failure Questionnaire. New York Heart Association class was assessed as a measure of the severity of heart failure. Construct validity of the PHQ-8 was evaluated by confirmatory factor analysis, Pearson correlation coefficients, and analysis of variance. Internal consistency reliability was estimated by using the Cronbach α. Results The sample was 63% men, with a mean age of 63 years, and 67% reported their race as white. Construct validity of the PHQ-8 was supported. The confirmatory factor analysis model reflected the emotional and somatic dimensions of depressive symptoms and displayed a good fit with the data. The χ2 value of the PHQ-8 was 24.75 with 18 degrees of freedom (P =.13) and the goodness-of-fit index was 0.98. The PHQ-8 was significantly correlated with the total and subscale scores on the Living With Heart Failure Questionnaire (P <.001 for all correlations). Differences in the PHQ-8 scores were found among New York Heart Association classes (F=20.4, P<.001). The PHQ-8 internal consistency reliability (Cronbach α) was 0.82. Conclusions The PHQ-8 demonstrated satisfactory validity and reliability; these results support its use to measure depressive symptoms in patients with heart failure.

1 August 2010 in Obesity
Verified
Journal Article
Closed access
PDF file
VBVeronique Bragulat
Veronique Bragulat
MDMario Dzemidzic
Mario Dzemidzic
CBCarolina Bruno
Carolina Bruno
CCCari A. Cox
Cari A. Cox
TTThomas Talavage
Thomas Talavage
DKDavid A. Kareken
David A. Kareken